阳性NELL-1-膜性病的临床和病理特征:一个案例系列研究
Kang Li1, Zheng Liang1, Xiaojing Liu1
1Department of Nephrology, Cangzhou Central Hospital, Cangzhou, China.
Frontiers in medicine
|September 22, 2025
概括
神经表皮生长因子类1蛋白 (NELL-1) 阳性膜性病显示出良好的治疗反应和高缓解率. 早期癌症查至关重要,因为许多患者患有恶性瘤,可以与NELL-1-阳性膜性脏病一起管理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫病理学 免疫病理学
- 在瘤学瘤学.
背景情况:
- 膜性病 (MN) 是成年人性综合征的主要原因.
- 虽然脂酶A2受体 (PLA2R) 和含有7A (THSD7A) 的1型血栓蛋白域是初级MN的主要标,但其他抗原正在被确定.
- 神经表皮生长因子类1蛋白 (NELL-1) 已成为MN病例的一个子集中的新目标抗原.
研究的目的:
- 描述NELL-1-阳性膜性病的临床,病理和治疗特征.
- 评估NELL-1-阳性MN患者的治疗策略和结果.
- 调查NELL-1-阳性MN和恶性瘤之间的关联.
主要方法:
- 在2010年至2021年期间诊断的非SLE MN患者的回顾性分析.
- 纳入标准:负的PLA2R和THSD7A染色,可用的脏组织.
- 收集的数据:临床,实验室,病理,治疗和结果参数.
主要成果:
- 确定了23名NELL-1-阳性,PLA2R阴性,THSD7A阴性MN患者.
- 高血压 (26.1%) 和综合征 (60.9%) 是常见的.
- 沿着质毛细管环观察到NELL-1沉积物;IgG1和IgG4是主要的免疫球蛋白子类.
- 通过免疫抑制疗法或支持性护理实现的高缓解率 (87.0%).
- 很大一部分 (26.1%) 患有恶性瘤,主要是肺癌.
结论:
- 尼尔-1-阳性MN的特点是特定的免疫球蛋白沉积模式 (IgG1,IgG4) 和一般有利的结局.
- 恶性病是显著的并发症,需要进行彻底的癌症查.
- 治疗潜在的恶性瘤可能会改善这些患者的结局.
相关概念视频
Nephrotic Syndrome I : Introduction
504
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
504
Nephrotic Syndrome II : Assessment and Medical Management
203
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
203


